Abstract
Two non-pathogenic scaffolds (represented by the filamentous bacteriophage fd and the dihydrolipoyl acetyltransferase E2 protein of the Bacillus stearothermophilus pyruvate dehydrogenase (PDH) complex) able to deliver human immunodeficiency virus (HIV)-1 antigenic determinants, were designed in our laboratories and investigated in controlled assay conditions. Based on a modification of the phage display technology, we developed an innovative concept for a safe and inexpensive vaccine in which conserved antigenic determinants of HIV-1 reverse transcriptase (RTase) were inserted into the N-terminal region of the major pVIII coat protein of bacteriophage fd virions. Analogously, we developed another antigen delivery system based on the E2 component from the PDH complex and capable of displaying large intact proteins on the surface of an icosahedral lattice. Our data show that both of these systems can deliver B and T epitopes to their respective presentation compartments in target cells and trigger a humoral response as well as a potent helper and cytolytic response in vitro and in vivo.
Keywords: vaccine, filamentous bacteriophage fd, phage display, dihydrolipoyl acetyltransferase
Current HIV Research
Title: Use of Fusion Proteins and Procaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection
Volume: 1 Issue: 4
Author(s): Piergiuseppe De Berardinis, Rossella Sartorius, Antonella Caivano, Dina Mascolo, Gonzalo J. Domingo, Giovanna Del Pozzo, Muriel Gaubin, Richard N. Perham, Dominique Piatier-Tonneau and John Guardiola
Affiliation:
Keywords: vaccine, filamentous bacteriophage fd, phage display, dihydrolipoyl acetyltransferase
Abstract: Two non-pathogenic scaffolds (represented by the filamentous bacteriophage fd and the dihydrolipoyl acetyltransferase E2 protein of the Bacillus stearothermophilus pyruvate dehydrogenase (PDH) complex) able to deliver human immunodeficiency virus (HIV)-1 antigenic determinants, were designed in our laboratories and investigated in controlled assay conditions. Based on a modification of the phage display technology, we developed an innovative concept for a safe and inexpensive vaccine in which conserved antigenic determinants of HIV-1 reverse transcriptase (RTase) were inserted into the N-terminal region of the major pVIII coat protein of bacteriophage fd virions. Analogously, we developed another antigen delivery system based on the E2 component from the PDH complex and capable of displaying large intact proteins on the surface of an icosahedral lattice. Our data show that both of these systems can deliver B and T epitopes to their respective presentation compartments in target cells and trigger a humoral response as well as a potent helper and cytolytic response in vitro and in vivo.
Export Options
About this article
Cite this article as:
Berardinis De Piergiuseppe, Sartorius Rossella, Caivano Antonella, Mascolo Dina, Domingo J. Gonzalo, Pozzo Del Giovanna, Gaubin Muriel, Perham N. Richard, Piatier-Tonneau Dominique and Guardiola John, Use of Fusion Proteins and Procaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection, Current HIV Research 2003; 1 (4) . https://dx.doi.org/10.2174/1570162033485168
DOI https://dx.doi.org/10.2174/1570162033485168 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Protozoan Parasite Metabolism: Glycolytic Enzymes in the Therapeutic Crosshairs
Current Medicinal Chemistry Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection
Current Drug Targets Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Transgenic Mice as a Model for Alzheimers Disease
Current Alzheimer Research Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer´s Disease
Current Neuropharmacology Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Schistosoma mansoni Antigens as Modulators of the Allergic Inflammatory Response in Asthma
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Recent Advances in Flavivirus Antiviral Drug Discovery and Vaccine Development
Recent Patents on Anti-Infective Drug Discovery The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?
CNS & Neurological Disorders - Drug Targets A Comprehensive Review of Alzheimer’s Association with Related Proteins: Pathological Role and Therapeutic Significance
Current Neuropharmacology Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Characterizing the Zika Virus Genome – A Bioinformatics Study
Current Computer-Aided Drug Design <i>In Silico</i> Approach to Predict the SARS-COV2 Derived Candidate MiRNAs as a Potential Antiviral Therapy
Current Drug Therapy Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture